The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that binds DNA in the form of a heterodimer with the AHR nuclear translocator protein (ARNT). Both proteins possess basic helix-loop-helix motifs. ARNT binds to the side of the xenobiotic responsive element (XRE) that resembles an E-box (the sequence recognized by the majority of other basic helix-loop-helix proteins), whereas AHR binds to the side of the XRE that does not conform to the E-box sequence. The basic region of ARNT closely resembles those of other E-box-binding proteins, whereas the "nominal basic region" of AHR (amino acids 27-39), although required for XRE binding, deviates from this consensus. By extensive mutational analysis it is shown here that an additional block of amino acids of AHR (from tyrosine 9 to lysine 20) that contains a highly basic segment is required for XRE binding and transcriptional activation. Deletion of the first nine amino acids negates XRE binding. Substitution of either tyrosine 9 or arginine 14 with alanine eliminates XRE binding, whereas alanine substitutions at certain other sites within the block reduce but do not eliminate binding. The reported absence of the first nine amino acids in the purified protein may therefore be artifactual. These results suggest that the amino acids of AHR involved in binding to the XRE constitute a novel DNA-binding domain, comprising amino acids located within and amino-terminal to the nominal basic region.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that binds DNA in the form of a heterodimer with the AHR nuclear translocator protein (ARNT). Both proteins possess basic helix-loop-helix motifs. ARNT binds to the side of the xenobiotic responsive element (XRE) that resembles an E-box (the sequence recognized by the majority of other basic helix-loop-helix proteins), whereas AHR binds to the side of the XRE that does not conform to the E-box sequence. The basic region of ARNT closely resembles those of other E-box-binding proteins, whereas the "nominal basic region" of AHR (amino acids 27-39), although required for XRE binding, deviates from this consensus. By extensive mutational analysis it is shown here that an additional block of amino acids of AHR (from tyrosine 9 to lysine 20) that contains a highly basic segment is required for XRE binding and transcriptional activation. Deletion of the first nine amino acids negates XRE binding. Substitution of either tyrosine 9 or arginine 14 with alanine eliminates XRE binding, whereas alanine substitutions at certain other sites within the block reduce but do not eliminate binding. The reported absence of the first nine amino acids in the purified protein may therefore be artifactual. These results suggest that the amino acids of AHR involved in binding to the XRE constitute a novel DNA-binding domain, comprising amino acids located within and amino-terminal to the nominal basic region. AHR 1 binds a variety of environmentally important carcinogens, including polycyclic aromatic and halogenated aromatic hydrocarbons, and mediates carcinogenesis by these compounds. The unliganded AHR is a component of a soluble cytosolic protein complex containing a 90-kDa heat shock protein and perhaps other proteins (1) . After binding ligand, AHR dissociates from the above complex and translocates to the nucleus, where it heterodimerizes with ARNT. The AHR/ARNT dimer binds specific DNA sequences, termed XREs, in the enhancer regions of certain enzymes involved in the metabolism of xenobiotics (reviewed in Ref. 2) .
Mouse AHR and ARNT are 20% identical in amino acid sequence and resemble each other, as well as the SIM (single minded) protein of Drosophila, in domain structure (3) (4) (5) . The three proteins contain bHLH motifs in their amino-terminal regions and share a more centrally located, approximately 300amino acid region of homology, which is also possessed by another Drosophila protein, PER (period). This PAS domain contains two approximately 50-amino acid degenerate direct repeats, termed PAS A and PAS B (6) . Recently, the PAS domain has been shown to mediate homodimerization of PER and heterodimerization of PER and SIM (7) as well as contributing toward dimerization of AHR with ARNT (5, 8) .
The bHLH motif is common to a number of transcription factors. Most bHLH-containing transcription factors bind as dimers to specific DNA sequences termed E-boxes (5Ј-CANNTG-3Ј) (reviewed in Ref. 9 ). The XRE sequence, to which the AHR/ARNT dimer binds, does not conform to the canonical E-box sequence. A consensus XRE sequence that can confer ligand-induced expression of a linked reporter gene has been identified as 5Ј-(T/G)NGCGTG(A/C)(G/C)A-3Ј (10 -12) . The consensus sequence for binding the AHR/ARNT dimer is less restrictive and has been identified as 5Ј-CGTG(A/C)(G/C/T)(A/ T)-3Ј. The four core nucleotides of the XRE (5Ј-CGTG-3Ј) are absolutely required for binding, whereas substitutions at other positions reduce binding affinity by up to about 8-fold (10, 11) . ARNT contacts the thymidine in the 5Ј-CGTG-3Ј core and thus in a region identical to an E-box half site (GTG), whereas AHR binds 5Ј proximal to this in a region differing from the E-box sequence (13) . Recent crystallographic data of the bHLH domains of the Max, USF, E47, and MyoD transcription factors binding to their specific target sequences have confirmed that their HLH domains are responsible, in part or entirely, for dimerization; that the basic domains are required for DNA binding; and that all contacts with nucleotide bases are restricted to amino acids in their basic domains (14 -17) . Consistent with these observations, we previously demonstrated the requirement of the basic domains and HLH domains in AHR and ARNT for TCDD-induced XRE binding and dimerization, respectively (5, 8) . Whereas the basic region of ARNT conforms well to the consensus for bHLH proteins, the basic region of AHR conforms only very poorly. Conformity only occurs at the extreme carboxyl-terminal end of the AHR basic region ( Fig. 1 ). This observation is compatible with the fact that AHR binds to the "non-E-box-like" side of the XRE sequence. We have assigned the boundaries of the AHR basic region by alignment to the corresponding region of the other bHLH proteins. Henceforth we will call this region the "nominal basic" region of AHR, because although it is less basic in character, it corresponds in position to the basic domain of other bHLH proteins.
AHR purified from mouse liver lacked the nine most amino-terminal amino acids encoded by the cloned cDNA for mouse AHR (3, 20) . Bradfield and co-workers (3) suggested that these nine amino acids constituted a leader peptide that is cleaved from the primary translation product to generate the mature protein. Our interest in the amino-terminal region of AHR developed from our observation that an AHR derivative lacking the putative leader peptide generated in vitro from the appropriately deleted cDNA is incapable of binding the XRE sequence in conjunction with ARNT (this paper). In the current work we perform a mutational analysis of AHR from its amino terminus to the nominal basic region. Our results define a novel region required for DNA binding and for in vitro and in vivo functionality. Our approach was first to perform deletion analysis to identify the amino terminus of the region required for DNA binding and then to substitute individual amino acids or blocks of amino acids with alanine residues in order to identify essential amino acids in the region. We utilized this "alanine scanning" strategy for two reasons. (i) The solved crystal structures of certain bHLH proteins demonstrate that their basic regions are ␣-helical when interacting with their specific DNA sequences (14 -17) . We therefore did not wish to compromise any ␣-helical conformation that may exist in the amino-terminal region of AHR. Substitution with alanine should not have any disruptive effect on ␣-helix formation, because alanine is the most common amino acid in protein ␣-helices (21) . (ii) Alanine lacks a reactive side group. Proline residues were left unaltered due to their potential structural role. Utilizing this approach we identify several amino acids located amino-terminal to the AHR nominal basic region that are required for TCDD-induced XRE binding and transcriptional activation. These are required in addition to amino acids located in the nominal basic region. 2 
MATERIALS AND METHODS

Generation of the AHR Expression Construct-
In an attempt to increase the in vitro expression of our AHR expression construct, pcDNAI/Neo/AHR (5), we added the ␤-globin 5Ј-untranslated region from the plasmid pT7␤hER (kindly provided by Dr. Bert W. O'Malley, Baylor College of Medicine, Houston, TX) and altered the second codon to conform to the optimum translation initiation sequence (while maintaining amino acid integrity) as follows. pcDNAI/Neo/AHR was transferred from pcDNAI/Neo to pcDNA3 (Invitrogen, San Diego, CA) utilizing unique HindIII and XbaI restriction sites, creating construct pcDNA3/AHR. A PCR product containing AHR sequence from base 1 to base 654 was generated with 5Ј primer L5/2 and 3Ј primer L4 using Ultma Polymerase (Perkin-Elmer). The primers are as follows: L5/2, 5Ј-GCTTCATCTCCAACATGTCTAGCGGCGCCAACATCACC-3Ј, and L4, 5Ј-GATCCTCGAGTCACAGCCGGCACC-3Ј. The PCR product was digested with restriction endonucleases AflIII and EcoRI and then ligated into the plasmid pT7␤hER digested with NcoI and EcoRI, which removes the human estrogen receptor insert (note: digestion with AflIII and NcoI results in compatible overhangs). The resulting construct was digested with restrictions enzymes HindIII and EcoRI to release a restriction fragment containing a 60-base pair ␤-globin 5Ј-untranslated leader sequence immediately upstream of AHR sequence bases 1-499 that was ligated into similarly digested pcDNA3/AHR, producing expression construct pcDNA3/␤AHR. Sequencing was performed to confirm PCR-generated AHR nucleotide bases 1-499. pcDNA3/␤AHR expressed approximately 3-fold higher levels of AHR protein compared with pcDNAI/Neo/AHR in a T7-coupled rabbit reticulocyte lysate system.
Generation of Amino-terminal Deletion Mutants-Amino-terminal deletion mutants were generated by PCR. The following 5Ј primers were used with 3Ј primer L4: N-2, 5Ј-TCTCCACCATGTCCATGGGT-GCCAACATCACCTATGCC-3Ј, NcoI; N-4, 5Ј-CCATGTCGAGCGTCAT-GAATATCACCTATGCCAGCCG-3Ј, BspHI; N-6, 5Ј-CGAGCGGCGC-CATCATGACTTATGCCAGCCGCAAGCG-3Ј, BspHI; N-7, 5Ј-GAG-GCGCCAACAACATGTATGCCAGCCGCAAGCGG-3Ј, AflIII; N-8, 5Ј-GATCAAGCTTACCATGGCCAGCCGCAAGC-3Ј, NcoI; and N-14, 5Ј-CCAGCCGCAAGCTCATGAAGCCGGTGCAGAAAACAG-3Ј, BspHI. PCR products were digested with EcoRI and the indicated enzyme (restriction endonuclease recognition sequence underlined) above and ligated to pT7␤hER digested with NcoI and EcoRI (note: digestion with AflIII, BspHI, and NcoI result in compatible overhangs). The resulting constructs were digested with restriction enzymes HindIII and EcoRI, and the released inserts were ligated to similarly digested pcDNA3/␤AHR. Two clones were isolated and analyzed for each mutation. All clones were sequenced to confirm their mutation. Plasmids were prepared by QIAGEN maxiprep according to the supplier's protocols (QIAGEN, Chatsworth, CA).
Generation of Alanine Scanning Mutants-Alanine scanning mutants CA (12) (13) (14) (15) (16) , CA (18 -21) , CA (22, 23, 25) , V18A, Q19A, K20A, and T21A were generated by the PCR methodology of overlap-extension (22) using Ultma Polymerase. Briefly, internal 5Ј and internal 3Ј primers (that contain complementary alanine codon substitutions in the 5Ј region of their sequences) were used in a primary PCR reaction with external 3Ј and external 5Ј primers, respectively. Using pcDNA3/␤AHR as template, the primary reactions result in alanine codon-substituted 5Ј and 3Ј PCR products. In a secondary PCR reaction, 5Ј and 3Ј PCR products are linked together to form a full-length alanine codon-substituted product and amplified using both partially complementary 5Ј and 3Ј products as template and only the external 5Ј and external 3Ј primers. The internal 5Ј and internal 3Ј primers for each clone are as follows: CA(12-16)5Ј, 5Ј-GCCGCGGCAGCCGCACCGGTGCAGAAAACAG-3Ј; CA(12-16)3Ј, 5Ј-TGCGGCTGCCGCGGCGCTAGCATAGGTGATGTTG-G-3Ј; CA(18 -21)5Ј, 5Ј-GCGGCGGCAGCAGTAAAGCCCATCCCC-3Ј; CA(18 -21)3Ј, 5Ј-TGCTGCCGCCGCAGGCTTGCGCCGC-3Ј; CA(22, 23,25)5Ј, 5Ј-GCAGCGCCCGCCCCAGCTGAAGGAATTAAG-3Ј; CA(22, 23,25)3Ј, 5Ј-GGCGGGCGCTGCTGTTTTCTGCACCGGC-3Ј; V18A/5Ј, 5Ј-CCGGCGCAGAAAACAGTAAAGC-3Ј; V18A/3Ј, 5Ј-CTGCGCCG-GCTTGCGCCG-3Ј; Q19A/5Ј, 5Ј-GTGGCGAAAACAGTAAAGCCC-3Ј; Q19A/3Ј, 5Ј-TTTCGCCACCGGCTTGCGC-3Ј; K20A/5Ј, 5Ј-CAGGCAA-CAGTAAAGCCCATC-3Ј; K20A/3Ј, 5Ј-TGTTGCCTGCACCGGCTTGC-3Ј; T21A/5Ј, 5Ј-AAAGCAGTAAAGCCCATCC-3Ј; and T21A/3Ј, 5Ј-TACT-GCTTTCTGCACCGGCTTG-3Ј. The external 5Ј primer corresponds to pcDNA3 sequence bases 839 -871. The external 3Ј primer corresponds to the complement of AHR sequence bases 225-237. The external 5Ј and 3Ј primers are as follows: external 5Ј, 5Ј-CACTGCTTACTGGCTTCTA-GAAATTAATACGAC-3Ј, and external 3Ј, 5Ј-GATCCTCGAGTCACTT-GGCCCTCAGG-3Ј. The secondary PCR products were digested with restriction enzymes HindIII and Bpu 1102I and then ligated to similarly digested pcDNA3/␤AHR. Alanine scanning mutants Y9A, S11A, R12A, K13A, R14A, R15A, and K16A were generated by PCR using Ultma Polymerase. 5Ј primers (that contain the alanine codon substitutions) were used with the external 3Ј PCR primer listed above. The 5Ј primers are as follows: Y9A, 5Ј-CACCATGTCTAGCGGCGCCAACATCACCGCTGCCAGCCGC-3Ј; S11A, 5Ј-CACCATGTCTAGCGGCGCCAACATCACCTATGCCGCCCG-CAAGCGG-3Ј; R12A, 5Ј-CACCATGTCTAGCGGCGCCAACATCACCT-ATGCCAGCGCCAAGCGGCGCAAGCC-3Ј; K13A, 5Ј-CACCATGTCT-AGCGGCGCCAACATCACCTATGCCAGCCGCGCGCGGCGCAAGC-C-3Ј; R14A, 5Ј-CACCATGTCTAGCGGCGCCAACATCACCTATGCCA-GCCGCAAGGCGCGCAAGCCG-3Ј; R15A, 5Ј-CACCATGTCTAGCGG-CGCCAACATCACCTATGCCAGCCGCAAGCGGGCCAAGCCGGTG-3Ј; and K16A, 5Ј-CACCATGTCTAGCGGCGCCAACATCACCTATGCCA-GCCGCAAGCGGCGCGCTCCGGTGCAG-3Ј. The PCR products were digested with restriction enzymes NarI and Bpu 1102I and then ligated to similarly digested pcDNA3/␤AHR. Two clones were isolated and analyzed for each mutation. All clones were sequenced to confirm their mutations. Plasmids were prepared by QIAGEN maxiprep according to the supplier's protocols (QIAGEN).
Cells and Cell Culture-The monkey kidney tumor cell line, CV-1, was cultured in nucleoside-free ␣-minimal essential medium (Irvine 2 S. G. Bacsi and O. Hankinson, manuscript in preparation.
FIG. 1. Alignment of basic regions of certain bHLH proteins that bind the CACGTG subclass of E-boxes. The consensus sequence shown is that derived from all mammalian bHLH protein that bind the CACGTG sequence (18, 19) . i, polar; @, aliphatic. Amino acids conforming to the consensus are shown in bold.
Scientific, Santa Ana, CA) supplemented with 10% heat-inactivated and dextran/charcoal-treated fetal calf serum.
In Vitro Transcription and Translation-The ARNT, AHR, and AHR mutant cDNAs were all contained in the pcDNA3 vector in the appropriate orientation for in vitro expression from the T7 polymerase promoter. The constructs were expressed in the TNT T7-coupled reticulocyte lysate system in the presence or the absence of [ 35 S]methionine (final concentration, 1 mCi/ml; specific activity, Ͼ1,000 Ci/mmol; Amersham Corp.) according to the protocol from the supplier (Promega, Madison, WI). All reactions were incubated for 90 min at 30°C. The degree of expression of each construct was assayed by subjecting an aliquot from the incubation performed in the presence of [ 35 S]methionine to SDS-polyacrylamide gel electrophoresis (PAGE) and subsequent quantitation on an AMBIS Radioanalytic Imaging System (AMBIS Inc., San Diego, CA) (henceforth referred to as ␤-scanning).
Immunoprecipitation of AHR Mutants-Full-length AHR and its mutant derivatives were synthesized in vitro in the presence of [ 35 S]methionine. Equimolar quantities of each protein were adjusted to 25 mM HEPES, 1.2 mM EDTA, 10% glycerol, 200 mM NaCl, 0.1% Nonidet P-40, pH 7.4 (immunoprecipitation buffer), in a final volume of 100 l. Affinity purified polyclonal antibody to AHR (23) or the corresponding preimmune immunoglobulin G fraction was added and incubated at room temperature for 1.5 h. The antigen-antibody complex was precipitated with protein A-Sepharose CL-4B beads (Pharmacia Biotech Inc.) for 1 h at room temperature. The pellets were washed four times with immunoprecipitation buffer, whereas the supernatants were precipitated with three volumes of acetone. Both fractions were boiled in SDS sample buffer (24) and subjected to SDS-PAGE on a 7.5% gel. In addition to exposure to x-ray film, the dried gels were analyzed by ␤-scanning to quantitate the amount of radioactivity in each immunoprecipitate. The relative immunoprecipitation capacity of each mutant was calculated as a percentage of the amount obtained from the immunoprecipitation of full-length AHR performed in the same experiment. The low signal generated by the preimmune IgG in the presence of TCDD was subtracted from the signal generated by the AHR antibodies in calculating the values for the amount of immunoprecipitated AHR protein.
Dimerization of AHR Mutants with Full-length ARNT-Full-length ARNT was synthesized in vitro in the presence of [ 35 S]methionine, whereas AHR (or its mutant derivatives) was synthesized in the absence of isotope. The in vitro transcription and translation reactions containing AHR (or its mutant derivatives) were mixed in a 1:1 molar ratio with ARNT, and the mixture was incubated with 10 nM TCDD (in Me 2 SO to a final concentration of 0.2% Me 2 SO) or solvent alone for 1.5 h at room temperature. The coimmunoprecipitation conditions and analysis were the same as described above for the immunoprecipitation of the AHR mutants. The relative TCDD-induced dimerization capacity of each mutant was calculated as a percentage of the amount of radiolabeled ARNT coimmunoprecipitated by full-length AHR in the same experiment. The low signal generated by the preimmune IgG in the presence of TCDD was subtracted from the signal generated by the AHR antibodies in calculating the values for the amount of coimmunoprecipitated ARNT protein in the presence of TCDD.
XRE Binding-In vitro synthesized, unlabeled AHR or its mutant derivatives were mixed with unlabeled full-length ARNT in a 1:1 molar ratio and incubated in the presence of 10 nM TCDD (in Me 2 SO to a final concentration of 0.2% Me 2 SO) or solvent alone at room temperature for 1.5 h. The mixture was then adjusted to 25 mM HEPES (pH 7.5), 200 mM KCl, 10 mM dithiothreitol, 10% glycerol, 5 mM EDTA, 50 g of poly(dI-dC)⅐poly(dI-dC)/ml, and the incubation was continued for 20 min at room temperature. The mixture was then incubated for an additional 20 min in the presence of a 32 P-labeled double-stranded synthetic oligonucleotide containing mouse XRE1 (23) . Samples were analyzed on a 4.5% nondenaturing polyacrylamide gel in 1 ϫ HTE buffer (200 mM HEPES, 100 mM Tris, 5 mM EDTA, pH 8.0). After exposure to x-ray film, the dried gels were used to quantitate the AHR⅐ARNT⅐XRE complex by ␤-scanning. The relative TCDD-induced XRE binding capacity of each AHR mutant protein was calculated as a percentage of the amount of AHR⅐ARNT⅐XRE complex obtained with full-length AHR and ARNT in the same experiment (subtracting the low background signal obtained from an empty lane).
In Vivo Functionality-The AHR cDNA constructs were cotransfected along with the CAT reporter plasmid, pMC6.3k (25) (7 g of each plasmid construct), into 5 ϫ 10 5 CV-1 cells/60-mm dish by the method of Chen and Okayama (26) . 16 h after transfection, cells were subjected to a 15% glycerol shock for 1.5 min and then refed media with or without 10 nM TCDD, followed by harvesting 24 h later. In an attempt to eliminate potential inducers of CYP1A1 in the medium used to grow the cells, the fetal calf serum was treated with dextran-coated charcoal and the medium was stored in the absence of light. Cell lysates were produced by three cycles of freezing (dry ice/ethanol) and thawing (37°C water bath). Endogenous acetyl transferases were inactivated by incubation at 65°C for 10 min. CAT assays were performed as described previously (27) . Protein concentrations were determined by the Bradford assay. The results were calculated as nmol product/mg protein/30 min. The relative in vivo activity of each AHR mutant protein was calculated as a percentage of the level of CAT activity obtained with full-length AHR in the same experiment. Table I . The full-length AHR construct, pcDNA3/␤AHR, was generated by alteration of pcDNAI/Neo/AHR (5) by the addition of a ␤-globin 5Ј-untranslated leader sequence and alteration of the second codon to the optimal translation initiation sequence (28) while maintaining the amino acid integrity and transfer into the expression vector pcDNA3. pcDNA3/␤AHR generated an approximately 3-fold greater amount of AHR protein than pcDNA1/Neo/AHR in a coupled in vitro T7 transcription/rabbit reticulocyte lysate translation system (data not shown). Aminoterminal deletion constructs N-2 through N-14 all have a methionine in the first position, like full-length AHR, and then have the indicated number of amino acids deleted beginning with amino acid 2. The above amino-terminal deletion mutations were constructed within the parent construct pcDNA3/␤AHR, but they do not maintain the optimum translation initiation sequence present in pcDNA3/␤AHR because of the requirement for an appropriate codon for the second amino acid of each mutant. All full-length clones (alanine scanning mutants) have the indicated alanine substitutions within the parent construct pcDNA3/␤AHR. Two clones were isolated, sequenced to confirm the mutation, and analyzed for each mutation.
RESULTS
Constructs-All constructs are presented in
XRE Binding-We previously showed that when equimolar amounts of in vitro synthesized ARNT and AHR were mixed in the absence or the presence of 10 nM TCDD, incubated with 32 P-labeled XRE 1, and then analyzed by gel mobility shift assay, a particular gel-shifted band was produced. This band was identified as the AHR⅐ARNT⅐XRE complex because it was not formed with either protein on its own and because its intensity was strongly increased by TCDD treatment, greatly reduced in the presence of a 100-fold excess of unlabeled XRE, and unaffected by a 100-fold excess of a mutant XRE (5). In the present experiments, AHR and its mutant proteins were mixed with an equimolar amount of full-length ARNT and the amount of AHR⅐ARNT⅐XRE complex generated was quantitated by ␤-scanning. The value for each mutant was calculated as a percentage of that produced by full-length AHR in the same experiment. The average results of three different experiments are presented in Table I and a representative autoradiogram is presented in Fig. 2 . In the current study we focused on the amino acids amino-terminal to the nominal basic region. We refer to this region as the "amino-terminal" region.
AHR amino-terminal deletion mutants N-2, N-4, N-6, and N-7 showed that loss (Ͻ1%) of TCDD-induced XRE binding capacity does not occur until removal of amino acid 9 (N-8). The results obtained with AHR mutant N-14 are consistent with this observation. Clustered alanine scanning mutants CA (12) (13) (14) (15) (16) , CA (18 -21) , and CA (22, 23, 25) were designed to identify the carboxyl-terminal terminal boundary of the domain in the amino-terminal region required for DNA binding. CA (12) (13) (14) (15) (16) showed a loss (Ͻ1%) of TCDD-induced XRE binding capacity, indicating that one or more of amino acid residues 12-16 is required for DNA binding. Mutant CA(18 -21) showed a significant (49%, p Ͻ 0.05) decrease in XRE binding capacity, whereas mutant CA(22,23,25) bound XRE at levels not signif-icantly different (p Ͼ 0.05) from full-length AHR. These results demonstrate that the carboxyl-terminal boundary in the amino-terminal region required for TCDD-induced XRE binding does not extend beyond amino acid 21.
Single alanine substitutions within amino acids 9 -21 allowed for the identification of specific amino acids within this region required for TCDD-induced XRE binding. Amino acids 9 (Y9A) and 14 (R14A) are required for DNA binding, as substitutions to alanines at these positions resulted in profound reductions (to Ͻ1 and 4%, respectively) of TCDD-induced XRE binding capacity compared with normal AHR. Alanine substitutions at amino acid positions 11 (S11A), 12 (R12A), 13 (K13A), 16 (K16A), and 20 (K20A) resulted in less marked but nevertheless significant (p Ͻ 0.05) reductions in XRE binding. AHR mutants R15A, V18A, Q19A, and T21A had TCDD-induced XRE binding capacities not significantly different from that of full-length AHR. Although AHR mutants N-8, N-14, CA (12) (13) (14) (15) (16) , and Y9A formed AHR⅐ARNT⅐XRE complexes at very low levels (Ͻ1%), these complexes were detectable upon extended exposure of the gels to film (data not shown), indicating that XRE binding was drastically reduced but not totally abolished.
Dimerization of AHR Mutants with ARNT-It is conceivable that the reduced XRE binding of one or more of the above AHR mutants is a secondary effect resulting from a reduction in the ability of the mutant AHR protein to dimerize with ARNT. We therefore tested all the AHR mutants having reduced XRE binding ability for their ability to dimerize with full-length ARNT. These experiments measured the amount of 35 S-labeled ARNT that could be coimmunoprecipitated with each mutant AHR protein after treatment of the ARNT-AHR mixture with affinity purified polyclonal antibodies to AHR. The AHR antibody preparation used in these assays was raised against a synthetic peptide corresponding to AHR amino acids 12-31. Because many of the AHR mutants contained substitutions or deletions within this region, we first determined whether immunoprecipitation of any of the AHR mutants was impaired. Equimolar quantities of in vitro synthesized 35 S-labeled fulllength AHR and AHR mutant proteins were incubated with the 
Summary of results obtained with AHR amino-terminal mutants
The means and standard errors for three to seven independent determinations of each parameter are shown.
FIG. 2. XRE binding analysis of AHR amino-terminal mutants.
Equimolar amounts of AHR and its mutant derivatives were mixed with equimolar amounts of ARNT, incubated with or without 10 nM TCDD as indicated and subjected to gel mobility shift analysis. The open arrow indicates the AHR⅐ARNT⅐XRE complex. The solid arrow indicates free probe. AHR-specific antibodies followed by precipitation with protein A-Sepharose. Immunoprecipitated proteins were analyzed along with the corresponding acetone precipitated supernatants by SDS-PAGE on a 7.5% gel. The amount of each immunoprecipitated protein was determined by quantitative radioanalytic imaging (␤-scanning) and calculated as a percentage of the amount of immunoprecipitate obtained with wild-type AHR. Representative results are presented in Fig. 3 . The AHR antibodies had reduced efficiency to immunoprecipitate only the proteins corresponding to mutant clones CA(12-16) and CA (18 -21) , for which the amounts of protein immunoprecipitated were 69 and 50%, respectively, of full-length AHR. The decreased immunoprecipitation efficiencies of these mutant proteins were taken into account in calculating their degrees of dimerization with ARNT in the following coimmunoprecipitation experiments. Unlabeled in vitro synthesized full-length or mutant AHR proteins were individually mixed with equimolar amounts of [ 35 S]methionine-labeled full-length ARNT protein in the presence or the absence of 10 nM TCDD, and the mixture was incubated at room temperature for 1.5 h to allow for heterodimerization. The mixtures were then treated with the affinity purified polyclonal antibodies to AHR, and the amounts of coimmunoprecipitated ARNT were analyzed by SDS-PAGE as described above. The value for each construct was calculated as a percentage of the amount of ARNT coimmunoprecipitated by full-length AHR in the same experiment.
The average values for all experiments are presented in Table  I . Representative results are shown in Fig. 4 .
The first six lanes of Fig. 4 represent the controls for the coimmunoprecipitation assay, utilized full-length AHR and ARNT incubated in the absence or the presence of TCDD, and were treated with AHR antibodies or the corresponding preimmune IgG, as indicated. The data demonstrate that TCDD treatment increased the amount of ARNT coimmunoprecipitated with AHR and that very little ARNT was precipitated from the coincubation mixture upon treatment with the preimmune IgG preparation. Therefore, the coimmunoprecipitates were efficient, inducible, and specific for AHR/ARNT heterodimers. All mutant proteins heterodimerized with ARNT as efficiently as full-length AHR, indicating that the reduced TCDD-induced XRE binding capacity is not due to loss of dimerization capacity.
In Vivo Functionality of the AHR Mutants-AHR cDNA constructs were cotransfected with the plasmid pMC6.3k into monkey kidney CV-1 cells. (pMC6.3k contains the region from about nucleotide Ϫ6300 to nucleotide ϩ2566 of the rat CYP1A1 gene fused to the CAT reporter gene.) The cells were then assayed for CAT activity in the presence of TCDD (Table I) . CV-1 cells were found by Western blot analysis to lack detectable AHR but to have levels of ARNT comparable with Hepa1c1c7 cells (which are highly TCDD-inducible for CYP1A1; data not shown). High level CAT activity was detected in CV-1 cells only when they were cotransfected with AHR. Thus cotransfection of pMC6.3k and the parent vector pcDNA3 (without insert) into CV-1 cells resulted in only 3% of the CAT activity obtained after transfecting pMC6.3k along with pcDNA3 containing full-length AHR. CAT activity in CV-1 cells transfected with wild-type AHR was only approximately 2-fold inducible by TCDD (data not show). A similar low level of inducibility has been previously observed by ourselves and others (8, 29, 30) in AHR-deficient cells transfected with AHR cDNA expression vectors and probably results from overexpression of AHR in the transfected cells. Each mutant AHR cDNA was assayed 3-7 times, and the cumulative results are presented in Table I .
Consistent with their dramatically reduced XRE binding activities (Ͻ4%), N-8, N-14, CA (12) (13) (14) (15) (16) , Y9A, and R14A generated markedly reduced CAT activities (16 -29% of the activity obtained with wild-type AHR) when cotransfected with pMC6.3k. In addition, the majority of other mutants (N-2, N-6, CA (18 -21) , S11A, and R12A) with significantly but less markedly reduced XRE binding capacities also generated significantly reduced CAT activities. The reductions in CAT activities for the mutants were not so marked as their reductions in XRE binding. Interestingly, a few mutant clones (CA (21, 22, 24) , R15A, Q19A, and T21A) that bound XRE at levels not significantly different from full-length AHR generated CAT activities that were significantly (p Ͻ 0.01) greater than full-length AHR. In summary, the CAT activities associated with the mutant AHR constructs reflected their in vitro XRE binding activities.
DISCUSSION
Poland and co-workers purified murine AHR and determined the amino-terminal amino acid sequence of their purified material (20) . The protein encoded by the AHR cDNA contains nine amino acids amino-terminal to the sequence obtained by Poland and co-workers (3, 4) . Poland and co-workers suggested that these nine amino acids constitute a leader peptide that is removed to generate the mature protein (3). However, our data show that removal of these nine amino acids and mutation of the ninth amino acid both eliminate XRE binding, suggesting that the absence of these amino acids in the protein purified by Poland and co-workers is an artifact of purification or sequencing.
XRE binding analysis of our AHR cDNA amino-terminal deletion mutants clearly demonstrated that DNA binding capacity was maintained until removal of the tyrosine at position 9 (N-8). The clustered alanine scanning clones defined the location of the carboxyl-terminal boundary of the amino-terminal region required for DNA-binding at Thr 21 . XRE binding analysis of alanine scanning mutants demonstrated that substitution of Tyr 9 or Arg 14 with alanine results in the loss of TCDD-induced XRE binding capacity. Alanine substitutions of amino acids at Ser 11 , Arg 12 , Lys 13 , Lys 16 , and Lys 20 significantly reduced DNA binding function but to a lesser degree. Many of the amino acids for which substitution with alanine reduces or eliminates XRE binding reside in a stretch of five basic amino acids (Arg 12 to Lys 16 ). The results of the coimmunoprecipitation experiments demonstrate that the decreased capacity of the mutant proteins to bind the XRE sequence is not due to reduced dimerization ability. Consistent with in vitro data, most AHR mutants that possessed reduced XRE binding capacities also generated significantly reduced in vivo CAT activities when cotransfected along with the pMC6.3k reporter plasmid (containing a CAT gene driven by the CYP1A1 enhancer/promoter) into CV-1 cells in the presence of TCDD. We have shown that AHR mutants that are completely unable to dimerize with ARNT and/or bind the XRE are completely unable to stimulate CAT activity in the above assay (8) . All the current mutants retained at least some XRE binding activity (although it was barely detectable in Y9A and equivalent mutants) and also generated significant CAT activity. The observation that the CAT activities of the mutants were not so severely reduced as their in vitro XRE binding activities is probably due to overexpression of the encoded AHR proteins in the transfected cells and/or to the fact that the CYP1A1 5Ј-flanking region present in pMC6.3k contains multiple functional XRE sequences, and these sequences can act in a cooperative fashion to stimulate transcription (31) . The highly basic region of amino acids 12-17 resembles a nuclear localization signal. However, because alanine substitutions within this region (except for arginine 14) only modestly reduce transcriptional activation of the CAT gene in the cotransfection assay and do not reduce CAT activities to any greater degree than they reduce XRE binding, this region cannot be required for nuclear localization. All the amino acids where we showed that alanine substitution affects XRE binding are conserved in mouse, rat, and human AHR (32) .
The basic region of ARNT conforms well to the consensus for the basic region of other bHLH protein that binds the E-box subclass CACGTG (Fig. 1) . In particular, arginine 102 of ARNT corresponds in position to arginine residues in other bHLH proteins that bind the above E-box subclass (14, 15, 33) . The nominal basic region of AHR also contains an arginine residue at the corresponding location. However, ARNT but not AHR contains a glutamic acid residue (glutamate 98 in ARNT) that is known, from x-ray crystallographic analysis of other bHLH proteins, to contact the CA base at each end of the E-box (14 -17). These observations are consistent with the findings that ARNT binds the E-box side of the XRE, that AHR binds the side of the E-box that does not resemble the XRE(1), and that a homodimer of ARNT can apparently bind the above E-box subclass (34, 35) and suggest that the half-sites for AHR and ARNT binding are divided by the third and fourth nucleotides in the above sequence.
The most plausible explanation for our observations is that the amino acids within the amino-terminal region that we identified as being required for DNA binding as well as amino acids within the nominal basic region (8) 2 directly contact DNA. However, physical analysis of the AHR⅐ARNT⅐XRE complex will be required to prove this. Crystallographic analysis of other bHLH proteins bound to their DNA targets have shown that the DNA binding domains of these proteins only extend over a span of 11-14 amino acids and that in each case the basic regions and helix 1 forms a continuous ␣-helix. In contrast, our results indicate that DNA binding by AHR extends from amino acid 9 to amino acid 39, a stretch of 31 amino acids. Furthermore, this segment contains four proline residues, strongly suggesting that it does not form a continuous ␣-helix. The Drosophila protein Hairy and mammalian Hes proteins (36, 37) contain a centrally located proline within their basic regions. AHR and ARNT, however, do not bind the Hairy/Hes N-box consensus sequence (5Ј-CANNAG-3Ј). Additionally, the presence of proline residues in AHR does not inhibit DNA binding to the extent that AHR acts as a negative regulator of transcription, as seen with the Id family of transcription factors that lack a basic region (38) . The bHLH protein E2F1, which binds the sequence 5Ј-GGCGGG-3Ј as a homodimer, resembles AHR with regard to the nonconformity of its basic region and the position of a proline residue in this region. However, unlike AHR, DNA binding by E2F1 does not require amino acid residues amino-terminal to its basic region (39) . Thus the region of AHR we have defined appears to represent a novel DNA-binding domain very different from that of other bHLH proteins.
Tyrosine 9, which is required for DNA binding, does not reside within a known protein kinase phosphorylation sequence. Serine 11 and threonine 21 are potential phosphorylation sites. Phosphorylation could be involved in DNA binding at the former amino acid residue, because alanine substitution at this site reduces XRE binding. Because alanine substitution at the latter residue does not affect DNA binding, phosphorylation at threonine 21 is not involved in DNA binding. However, although some indirect evidence exists for the involvement of phosphorylation of AHR in XRE binding (40 -44) , direct analysis of phosphorylation sites on AHR suggests that no phosphorylations occur within the basic or amino-terminal regions of the protein (45) . Alanine substitution at arginine 14 has a much greater effect on DNA binding than substitutions at FIG. 4 . Dimerization of AHR amino-terminal mutants with full-length ARNT. AHR and its mutant derivatives were incubated with equimolar amounts of radiolabeled ARNT. The AHR antibody preparation was used throughout, except in the fifth and sixth lanes, where preimmune IgG (PI) was used. Immunoprecipitated pellets and acetone-precipitated supernatants were subjected to 7.5% PAGE. Ϫ, no TCDD treatment; ϩ, TCDD treatment; p, immunoprecipitate; s, supernatant. The positions of the molecular mass markers are indicated on the left. other positions within the highly basic region encompassing amino acids 12-16, suggesting that Arg 14 may contact a DNA base and that the other amino acids in this block may not play a role in DNA sequence discrimination and may contact the phosphodiester backbone. A similar argument suggests that tyrosine 9 may also contact a base(s) in DNA.
